Fresenius Medical Care AG & Co. (NYSE:FMS) Stock Rating Lowered by Morgan Stanley

Fresenius Medical Care AG & Co. (NYSE:FMS) was downgraded by equities research analysts at Morgan Stanley from an “equal weight” rating to an “underweight” rating in a research note issued to investors on Friday, The Fly reports.

FMS has been the subject of several other reports. JPMorgan Chase & Co. restated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Thursday, August 29th. DZ Bank reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research note on Wednesday, October 30th. Redburn Partners reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research note on Wednesday, October 23rd. Royal Bank of Canada reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a report on Monday, August 19th. Finally, ValuEngine raised Fresenius Medical Care AG & Co. from a “sell” rating to a “hold” rating in a research note on Tuesday, December 3rd. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $45.81.

Shares of NYSE FMS opened at $35.67 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 0.75. The firm has a market cap of $22.16 billion, a PE ratio of 14.99, a P/E/G ratio of 3.64 and a beta of 1.46. The company’s fifty day simple moving average is $35.87 and its 200 day simple moving average is $35.92. Fresenius Medical Care AG & Co. has a 12-month low of $30.99 and a 12-month high of $42.75.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. Fresenius Medical Care AG & Co. had a net margin of 7.47% and a return on equity of 9.92%. The firm had revenue of $4.91 billion during the quarter, compared to the consensus estimate of $4.72 billion. On average, equities analysts predict that Fresenius Medical Care AG & Co. will post 2.44 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FMS. NEXT Financial Group Inc bought a new stake in shares of Fresenius Medical Care AG & Co. during the second quarter worth about $29,000. Old North State Trust LLC acquired a new position in Fresenius Medical Care AG & Co. during the 3rd quarter valued at about $29,000. Tower Research Capital LLC TRC boosted its stake in Fresenius Medical Care AG & Co. by 212.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,078 shares of the company’s stock valued at $42,000 after purchasing an additional 733 shares during the last quarter. Whittier Trust Co. acquired a new position in Fresenius Medical Care AG & Co. during the 3rd quarter valued at about $46,000. Finally, Ladenburg Thalmann Financial Services Inc. increased its holdings in Fresenius Medical Care AG & Co. by 70.0% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,853 shares of the company’s stock worth $73,000 after purchasing an additional 763 shares in the last quarter. Hedge funds and other institutional investors own 1.40% of the company’s stock.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also: Market Capitalization in the Stock Market

The Fly

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit